Gaudium IVF and Women Health Limited, India’s first publicly listed IVF chain, today kicked off its first milestone in the company’s planned 19-centre expansion, as outlined in the growth roadmap shared with investors during its IPO. The launch reinforces the company’s commitment to making high-quality, technology-driven fertility care more accessible to aspiring parents through a standardised clinical and laboratory model that combines AI-powered innovation with the highest standards of clinical excellence, patient safety, and ethical care.

AI-Powered Signature Labs

Strategically located in South Delhi, the new centre offers comprehensive fertility care under one roof, combining experienced fertility specialists, advanced reproductive medicine, and Gaudium IVF’s standardised clinical protocols. At the heart of the new centre is the Gaudium Signature Lab, the company’s proprietary laboratory framework that integrates advanced embryology, AI-powered technologies, and internationally benchmarked quality standards to create an optimal environment for embryo development.

Expansion and Future Plans

As Gaudium IVF expands its network, the Signature Lab model will be replicated across every new centre, ensuring patients experience the same high standards of precision, safety, and clinical excellence, irrespective of location. The launch comes at a time when demand for specialised fertility care continues to grow across India, driven by delayed parenthood, changing lifestyles, and increasing awareness of assisted reproductive technologies.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Gaudium gains 25.7% over three months and trades near its 52-week highs. Premium net margins of 23.4% demonstrate strong cost discipline and a wide competitive moat. Revenue grows at 33.1% and profits at 21.9% CAGR. Both numbers are exceptional. Buyers show up with 2.1x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 33.1% and profits at 21.9%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.53 premium is usually justified. Check Fundamentals of Gaudium IVF and Women Health Limited.

Gaudium IVF and Women Health Limited (NSE: GAUDIUMIVF) announced its audited financial results for the quarter and financial year ended March 31, 2026, marking a significant milestone with record revenue, EBITDA, and PAT for Q4FY26. The company reported a revenue of ₹30.35 crore, marking a 12.74% year-over-year growth. The EBITDA stood at ₹12.17 crore, a robust 39.56% increase from the previous year, with an EBITDA margin of 40.10%. The Profit After Tax (PAT) for the quarter was ₹8.36 crore, a remarkable 29.46% increase. These impressive figures underscore Gaudium IVF’s strong performance and growth trajectory.

Quarterly Performance

The company’s Q4FY26 revenue from operations stood at ₹30.35 crore, up from ₹26.92 crore in Q4FY25. The EBITDA for the quarter was ₹12.17 crore, compared to ₹8.72 crore in the same period last year. The PAT for Q4FY26 was ₹8.36 crore, significantly higher than the ₹6.45 crore reported in Q4FY25. These results highlight the company’s operational efficiency and strategic growth initiatives.

Full Year Performance

For the full fiscal year 2026, Gaudium IVF reported a consolidated revenue of ₹104.35 crore, marking a 47.56% year-over-year growth. The EBITDA for FY26 was ₹37.70 crore, up from ₹28.63 crore in FY25, with an EBITDA margin of 36.13%. The PAT for FY26 was ₹24.48 crore, a 27.69% increase from the previous year. These figures reflect the company’s sustained growth and operational excellence.

Commenting on the performance, Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF and Women Health Limited, said: “FY26 has been a defining year for Gaudium IVF, the year we transitioned into a listed, institutional and scalable fertility platform. Q4 capped this journey with steady patient volumes across our mature centres and continued discipline on cost, which together translated into the growth you see in revenue, EBITDA and PAT for the quarter and the year. Looking ahead, our priority is execution. With a debt-light balance sheet post-IPO, a clearly funded expansion plan, and an underpenetrated Indian fertility market, we believe Gaudium IVF is well placed to compound growth responsibly over the coming years.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited. Here’s a quick read on where the business and the stock stand today.